Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung

NCT05228795 | Unknown

• 1 other identifier: Soh-Med-22-01-29
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Lung carcinoma is the second most common cancer and a leading cause of cancer-related mortality worldwide. In Egypt, lung carcinoma ranks the 5th among all cancer cases. Malignant mesothelioma is an aggressive neoplasm that arises from mesothelial cells which form the lining of the pleural. There is a strong resemblance between epithelioid mesothelioma and lung adenocarcinoma, some of peripheral lung adenocarcinoma or SCC present with pleurotropic growth like mesothelioma. Glypican-1 (GPC1) is one the six glypican family members. It is one of cell surface heparan sulfate proteoglycans that acts as a growth factor signaling. The aim of this study is to evaluate the immunohistochemical expression of Glypican-1 in pleural epitheloid mesothelioma, lung adenocarcinoma and lung SCC

Conditions

Lung Cancer Adenocarcinoma; Lung Cancer Squamous Cell; Mesothelioma; Lung

Keywords

Glypican-1; Epitheloid mesothelioma; Lung adenocarcinoma; Lung SCC

Outcome Measures

Primary Outcomes (2)

• evaluate the immunohistochemical expression of Glypican-1 in pleural epitheloid mesothelioma, lung adenocarcinoma and lung SCC

  Immunohistochemical study

  1 month

• to correlate its expression with some known clinico-pathological parameters, to evaluate its diagnostic and prognostic role.

  Statistical analysis

  1 month

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

sixty specimens including: 20 cases of pleural epitheloid mesothelioma, 20 cases of lung adenocarcinoma and 20 cases of lung SCC obtained from patients who underwent excisional biopsy in Cardiothoracic Department, according to local Ethical Committee regulations, to be examined in the Pathology Laboratory of Sohag Faculty of Medicine. From January 2022 till completing the sample size.

You may qualify if:

• Patients with pleural epithelioid mesothelioma and lung adenocarcinoma and SCC who underwent surgery

You may not qualify if:

• Patients received pre-operative chemotherapy or radiotherapy.
• Patients with insufficient clinical data.
• Specimens with extensive necrosis
• Tiny specimens which are insufficient for accurate diagnosis.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Faculty of Medicine, Sohag University

Sohag, Egypt

RECRUITING

MeSH Terms

Conditions

Adenocarcinoma of Lung; Mesothelioma

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Adenoma; Neoplasms, Mesothelial

Study Officials

• Nagwa Ahmed, Lecturer

  Sohag University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nagwa Ahmed, Lecturer

CONTACT

01017415996; nagwa.sadek@med.sohag.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer at Pathology Department, Faculty of Medicine, Sohag University

Study Record Dates

• First Submitted: January 27, 2022
• First Posted: February 8, 2022
• Study Start: February 1, 2022
• Primary Completion: June 1, 2022
• Study Completion: December 1, 2022
• Last Updated: February 8, 2022

Record last verified: 2022-01

Locations

EG (1)